Compare F.N.B. Corporation Common Stock (FNB) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F.N.B. Corporation Common Stock vs IDEXX Laboratories, Inc. — how do they compare? F.N.B. Corporation Common Stock trades at $16.96 (market cap $6.03B), while IDEXX Laboratories, Inc. trades at $532.96 (market cap $41.68B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.9× F.N.B. Corporation Common Stock's market cap, and F.N.B. Corporation Common Stock pays a 3.07% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold F.N.B. Corporation Common Stock for 0 Days and IDEXX Laboratories, Inc. for 47 Days on average.
| FNB | IDXX | |
|---|---|---|
Market Cap | $6.03B | $41.68B |
Volume | 7,117,178 | 824,427 |
Sector | Financials | Health |
52-Week High | $19.49 | $766.68 |
52-Week Low | $14.65 | $504.70 |
Typical Hold Time | 0 Days | 47 Days |
Enterprise Value | $10.52B | $42.58B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNB trades at $17.05, down 0.76% on the day, with a neutral technical signal. The stock shows solid fundamentals with a P/E of 10.15 and P/B of 0.89, indicating potential undervaluation. Recent earnings have been mixed, with Q2 2026 beating estimates but Q1 missing. Revenue remains stable at $1.77 billion for 2025, with a strong net income margin of 33.04%. Analyst sentiment is positive, with 13 buy ratings and a consensus price target of $20.80.
The outlook for FNB is cautiously optimistic, supported by strong profitability and a favorable analyst consensus. Key opportunities include potential upside to the price target and consistent dividend payments. Risks involve earnings volatility, as seen in recent quarters, and competitive pressures in the banking sector. Investors should weigh the attractive valuation against execution risks and market conditions.
IDEXX Laboratories (IDXX) trades at $520.31, down 0.69% with neutral technical signals. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $4.27 versus $3.94, maintaining a 3-quarter beat streak. Revenue growth accelerated to $4.3B in 2025 with robust 25.03% net margins and exceptional 74.21% ROE. Recent acquisitions like CoVetAI expand veterinary workflow capabilities while management reaffirmed long-term growth targets at the Morgan Stanley Healthcare Conference.
Wall Street maintains bullish sentiment with 56.5% buy ratings and $665 consensus target implying 28% upside. Strong profitability and diagnostic innovation pipeline support growth, though elevated P/E of 37.2 and recent insider selling pose valuation concerns. Key risks include FX headwinds, weaker U.S. vet visits, and competitive pressures in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About F.N.B. Corporation Common Stock
F.N.B. Corporation is a diversified financial services holding company headquartered in Pittsburgh, Pennsylvania, operating through its lead subsidiary, First National Bank of Pennsylvania. It provides commercial banking, consumer banking, wealth management, and insurance through more than 350 banking offices across seven states and Washington, D.C.
Read more on FNB →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
